JP7132954B2 - 改善された免疫原性及び結合活性を提供する２価又は多価コンジュゲート多糖を含む多価コンジュゲートワクチン - Google Patents

改善された免疫原性及び結合活性を提供する２価又は多価コンジュゲート多糖を含む多価コンジュゲートワクチン Download PDF

Info

Publication number
JP7132954B2
JP7132954B2 JP2019567989A JP2019567989A JP7132954B2 JP 7132954 B2 JP7132954 B2 JP 7132954B2 JP 2019567989 A JP2019567989 A JP 2019567989A JP 2019567989 A JP2019567989 A JP 2019567989A JP 7132954 B2 JP7132954 B2 JP 7132954B2
Authority
JP
Japan
Prior art keywords
group
bivalent
composition
polysaccharides
streptococcus pneumoniae
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019567989A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020523323A5 (enExample
JP2020523323A (ja
Inventor
カプレ，スバッシュ・ブイ
ダッタ，アヌープ・ケイ
Original Assignee
インベントプライズ リミテッド ライアビリティ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インベントプライズ リミテッド ライアビリティ カンパニー filed Critical インベントプライズ リミテッド ライアビリティ カンパニー
Publication of JP2020523323A publication Critical patent/JP2020523323A/ja
Publication of JP2020523323A5 publication Critical patent/JP2020523323A5/ja
Application granted granted Critical
Publication of JP7132954B2 publication Critical patent/JP7132954B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019567989A 2017-06-10 2018-06-11 改善された免疫原性及び結合活性を提供する２価又は多価コンジュゲート多糖を含む多価コンジュゲートワクチン Active JP7132954B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762517905P 2017-06-10 2017-06-10
US62/517,905 2017-06-10
PCT/US2018/036868 WO2018227177A1 (en) 2017-06-10 2018-06-11 Multivalent conjugate vaccines with bivalent or multivalent conjugate polysaccharides that provide improved immunogenicity and avidity

Publications (3)

Publication Number Publication Date
JP2020523323A JP2020523323A (ja) 2020-08-06
JP2020523323A5 JP2020523323A5 (enExample) 2021-04-30
JP7132954B2 true JP7132954B2 (ja) 2022-09-07

Family

ID=64562792

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019567989A Active JP7132954B2 (ja) 2017-06-10 2018-06-11 改善された免疫原性及び結合活性を提供する２価又は多価コンジュゲート多糖を含む多価コンジュゲートワクチン

Country Status (12)

Country Link
US (1) US10688170B2 (enExample)
EP (1) EP3634481A4 (enExample)
JP (1) JP7132954B2 (enExample)
KR (3) KR20240018697A (enExample)
CN (2) CN111132691A (enExample)
AU (1) AU2018280272C1 (enExample)
BR (1) BR112019026192B1 (enExample)
CA (1) CA3066911C (enExample)
MX (2) MX2019014829A (enExample)
MY (1) MY198400A (enExample)
WO (1) WO2018227177A1 (enExample)
ZA (1) ZA201908528B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108025053A (zh) * 2015-04-16 2018-05-11 创赏有限公司 百日咳杆菌免疫原性的疫苗组合物
KR102800419B1 (ko) * 2015-07-21 2025-04-25 화이자 인코포레이티드 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
CN111132691A (zh) 2017-06-10 2020-05-08 创赏有限公司 提供改善的免疫原性和亲合力的具有二价或多价缀合物多糖的多价缀合物疫苗
MX2020005779A (es) 2017-12-06 2020-10-28 Merck Sharp & Dohme Composiciones que comprenden conjugados de polisacarido de streptococcus pneumoniae con proteina y metodos de uso de estos.
WO2020121159A1 (en) * 2018-12-12 2020-06-18 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
KR20240169145A (ko) 2018-12-19 2024-12-02 머크 샤프 앤드 돔 엘엘씨 스트렙토코쿠스 뉴모니아에 폴리사카라이드-단백질 접합체를 포함하는 조성물 및 그의 사용 방법
BR112021024393A8 (pt) * 2019-06-05 2023-01-31 Merck Sharp & Dohme Um conjugado de polissacarídeo-proteína pneumocócico de sorotipo 35b imunogênico e processo de conjugação para fabricar o mesmo
CN110804097B (zh) * 2019-10-30 2021-02-26 云南沃森生物技术股份有限公司 一种同时制备两种单克隆抗体的方法
EP4090364A4 (en) * 2020-01-17 2024-02-21 Inventprise, Inc. MULTIVALENT STREPTOCOCCAL VACCINES
CN111643661A (zh) * 2020-06-08 2020-09-11 王竹林 新型免疫佐剂、化合物及其应用
EP4192499A4 (en) * 2020-08-10 2024-09-25 Inventprise, Inc. Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24f
EP4240410A1 (en) * 2020-11-04 2023-09-13 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
CN113173977B (zh) * 2021-05-12 2024-03-29 江苏坤力生物制药有限责任公司 一种双功能抗原、其制备方法及应用
CN115721709A (zh) * 2021-08-27 2023-03-03 康希诺生物股份公司 一种肺炎球菌结合疫苗制备方法
GB2614916A (en) * 2022-01-25 2023-07-26 Optivalent Ltd Intradermal vaccine complement
KR20240145520A (ko) * 2022-03-18 2024-10-07 덴카 주식회사 링커에 의해 연결된 캡시드 단백질을 포함하는 바이러스 유사입자
CN117643624A (zh) * 2024-01-30 2024-03-05 成都康华生物制品股份有限公司 一种双价多糖结合疫苗的制备方法及双价多糖结合疫苗

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005516932A (ja) 2001-12-18 2005-06-09 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 肺炎連鎖球菌ワクチン
JP2008525423A (ja) 2004-12-24 2008-07-17 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル 糖結合体ワクチン
JP2009532439A (ja) 2006-04-07 2009-09-10 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
JP2010500354A (ja) 2006-08-07 2010-01-07 プレジデント アンド フェロウズ オブ ハーバード カレッジ タンパク質マトリックスワクチンおよびそのようなワクチンの製造方法および投与方法
JP2010531329A (ja) 2007-06-26 2010-09-24 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 肺炎連鎖球菌莢膜多糖コンジュゲートを含むワクチン
JP2010532793A (ja) 2007-06-20 2010-10-14 バクスター・インターナショナル・インコーポレイテッド コンジュゲートワクチン用修飾多糖
JP2013518891A (ja) 2010-02-09 2013-05-23 メルク・シャープ・エンド・ドーム・コーポレイション １５価肺炎球菌多糖−タンパク質コンジュゲートワクチン組成物
JP2013521315A (ja) 2010-03-09 2013-06-10 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 担体タンパク質にコンジュゲートされた肺炎連鎖球菌多糖類を含んでなる免疫原性組成物
JP2015522692A (ja) 2012-07-16 2015-08-06 ファイザー・インク 糖およびその使用
JP2015524839A (ja) 2012-08-16 2015-08-27 ファイザー・インク 糖鎖付加プロセスおよび組成物
WO2015175355A1 (en) 2014-05-11 2015-11-19 Kanvax Biopharmaceuticals Ltd Compositions and methods of enhancing immunogenicity of polysaccharide protein conjugates
WO2016207905A2 (en) 2015-06-23 2016-12-29 Biological E Limited Multivalent pneumococcal conjugate vaccine
JP2017505792A (ja) 2014-02-14 2017-02-23 ファイザー・インク 免疫原性糖タンパク質コンジュゲート
JP2017509656A (ja) 2014-01-21 2017-04-06 ファイザー・インク コンジュゲート化莢膜糖類抗原を含む免疫原性組成物およびその使用
WO2017085586A1 (en) 2015-11-20 2017-05-26 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902506A (en) 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US5360897A (en) 1981-08-31 1994-11-01 The University Of Rochester Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4686102A (en) 1984-04-12 1987-08-11 American Cyanamid Company Multivalent pneumococcal vaccine and preparation thereof
CA2059693C (en) 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
CA2059692C (en) 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
US5371197A (en) 1991-09-24 1994-12-06 Merck & Co., Inc. Protein-dimeric polysaccharide conjugate vaccine
US5849301A (en) 1993-09-22 1998-12-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine Producing immunogenic constructs using soluable carbohydrates activated via organic cyanylating reagents
US5565204A (en) 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US5681570A (en) 1995-01-12 1997-10-28 Connaught Laboratories Limited Immunogenic conjugate molecules
US5866132A (en) 1995-06-07 1999-02-02 Alberta Research Council Immunogenic oligosaccharide compositions
FR2763244B1 (fr) 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
US6224880B1 (en) 1997-09-24 2001-05-01 Merck & Co., Inc. Immunization against Streptococcus pneumoniae using conjugated and unconjugated pneumoccocal polysaccharide vaccines
US5965714A (en) 1997-10-02 1999-10-12 Connaught Laboratories, Inc. Method for the covalent attachment of polysaccharides to protein molecules
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
US6903184B1 (en) 1998-03-02 2005-06-07 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Multiple antigenic peptides immunogenic against Streptococcus pneumonia
ES2343492T3 (es) 1998-04-07 2010-08-02 Medimmune, Llc Derivados de proteinas neumococicas de union a colina para vacunas.
EP1034792A1 (en) 1999-03-11 2000-09-13 Pasteur Merieux Serums Et Vaccins Intranasal delivery of pneumococcal polysaccharide vaccines
EP1162999B1 (en) 1999-03-19 2006-11-29 Glaxosmithkline Biologicals S.A. Vaccine against Streptococcus pneumoniae
FR2806304B1 (fr) 2000-03-17 2002-05-10 Aventis Pasteur Conjugues polysaccharidiques du pneumocoque a usage vaccinal contre le tetanos et la diphterie
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
WO2003094960A2 (en) 2002-05-14 2003-11-20 Chiron Srl Mucosal combination vaccines for bacterial meningitis
WO2004000802A2 (en) 2002-06-20 2003-12-31 University Of Maryland Biotechnology Institute Scaffolded maleimide clusters for multivalent peptide assembly
AU2003257003A1 (en) * 2002-07-30 2004-02-16 Baxter Healthcare S.A. Chimeric multivalent polysaccharide conjugate vaccines
DE602004010376T2 (de) 2003-03-13 2008-10-23 Glaxosmithkline Biologicals S.A. Verfahren zur reinigung von bakteriellem cytolysin
US8048432B2 (en) 2003-08-06 2011-11-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Polysaccharide-protein conjugate vaccines
BRPI0413309B8 (pt) 2003-08-06 2021-05-25 The Government Of The Us Secretary Department Of Health And Human Services método para a preparação de uma vacina conjugada de polissacarídeo-proteína
US20050118199A1 (en) 2003-10-07 2005-06-02 Esser Mark T. Process for covalently conjugating polysaccharides to microspheres or biomolecules
US20090317412A1 (en) * 2004-06-04 2009-12-24 Alexander Jeffery L Induction of an immune response against streptococcus pneumoniae polyaccharides
CN104815327A (zh) 2005-04-08 2015-08-05 惠氏有限责任公司 多价肺炎球菌多糖-蛋白质缀合物组合物
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US7709001B2 (en) * 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
CN101287488B (zh) 2005-09-01 2013-01-30 诺华疫苗和诊断有限两合公司 含血清群c脑膜炎球菌的多价疫苗
PL3017827T3 (pl) 2005-12-22 2019-04-30 Glaxosmithkline Biologicals Sa Szczepionka z koniugatem polisacharydu pneumokokowego
AU2006336520B2 (en) 2005-12-28 2011-09-15 The Uab Research Foundation Pneumococcal serotypes
JP5285431B2 (ja) 2005-12-28 2013-09-11 ザ ユーエイビー リサーチ ファウンデイション 肺炎球菌血清型
US8575319B2 (en) 2006-03-10 2013-11-05 The Regents Of The University Of California Cleavable vaccine compositions and uses thereof and methods of making and using the same
KR101711903B1 (ko) 2006-03-17 2017-03-03 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카 에즈 레프리젠티드 바이 더 세크러테리 오브 더 디파트먼트 오브 헬스 앤드 휴먼 서비시즈 복합 다가 면역원성 콘쥬게이트의 제조 방법
AR060188A1 (es) 2006-03-30 2008-05-28 Glaxosmithkline Biolog Sa Procedimiento de conjugacion
WO2007127668A2 (en) 2006-04-26 2007-11-08 Wyeth Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations
US8808707B1 (en) 2006-05-08 2014-08-19 Wyeth Llc Pneumococcal dosing regimen
PT2129693T (pt) 2007-03-23 2017-02-14 Wyeth Llc Processo de purificação abreviado para a produção de polissacáridos capsulares de streptococcus pneumoniae
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
WO2009094730A1 (en) 2008-02-01 2009-08-06 Newcastle Innovation Limited Vaccine compositions
EP2108656A1 (en) 2008-03-19 2009-10-14 Beninati, Concetta Antigenic protein fragments of streptococcus pneumoniae
HUE037465T2 (hu) 2008-12-18 2018-09-28 Wyeth Llc Eljárás 19A szerotípusú streptococcus pneumoniae poliszacharidok molekulatömegének szabályozására
KR101450958B1 (ko) 2009-04-30 2014-10-15 콜레이 파마시티컬 그룹, 인코포레이티드 폐렴구균 백신 및 그의 용도
WO2010141312A2 (en) 2009-06-01 2010-12-09 Wake Forest University Health Sciences Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same
BR112012005349A2 (pt) 2009-09-09 2016-03-29 Matrivax Res & Dev Corp composição imunogênica, seu método de fabricação, método de fabricação de uma composição de vacina de matriz de proteína, e uso
ES2614807T3 (es) 2010-06-04 2017-06-02 Wyeth Llc Formulaciones vacunales
ES2864764T3 (es) 2011-05-11 2021-10-14 Childrens Medical Center Composición inmunogénica que presenta múltiples antígenos, y métodos y usos de la misma
CN103582496B (zh) 2011-06-03 2016-05-11 3M创新有限公司 具有聚乙二醇链段的异双官能连接基以及由其制成的免疫应答调节剂缀合物
CN103656631B (zh) * 2012-09-24 2015-08-19 北京科兴中维生物技术有限公司 多价肺炎球菌荚膜多糖-蛋白缀合物组合物及其制备方法
GB201218660D0 (en) * 2012-10-17 2012-11-28 Glaxosmithkline Biolog Sa Immunogenic composition
CN104870463B (zh) 2012-12-20 2018-09-28 辉瑞公司 糖缀合方法
ITMI20130142A1 (it) 2013-01-31 2014-08-01 Biosynth Srl Vaccini glicoconiugati comprendenti unita' di base di un costrutto molecolare esprimente epitopi multipli incorporati
US20150079132A1 (en) 2013-09-17 2015-03-19 Path Evoking protection against streptotoccus pneumoniae incorporating b-cell and t-cell pneumococcal protein antigens and pneumococcal polysaccharides delivered concomitantly
BR112016015835B1 (pt) 2014-01-21 2023-12-26 Pfizer Inc Processo de preparação de conjugados compreendendo polissacarídeos capsulares de streptococcus pneumoniae
CA2937190A1 (en) 2014-01-21 2015-07-30 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
GB201406569D0 (en) 2014-04-11 2014-05-28 Stabilitech Ltd Vaccine compositions
WO2015183676A1 (en) 2014-05-29 2015-12-03 Kapre Subhash V Synthetic peptides as carriers for conjugation with polysaccharides
MX2017004495A (es) 2014-10-09 2017-12-18 Msd Wellcome Trust Hilleman Laboratories Pvt Ltd Proceso mejorado para la conjugacion y conjugados sinteticos de oligosacarido-proteina novedosos obtenidos del mismo.
KR102800419B1 (ko) 2015-07-21 2025-04-25 화이자 인코포레이티드 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
CN111132691A (zh) 2017-06-10 2020-05-08 创赏有限公司 提供改善的免疫原性和亲合力的具有二价或多价缀合物多糖的多价缀合物疫苗

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005516932A (ja) 2001-12-18 2005-06-09 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 肺炎連鎖球菌ワクチン
JP2008525423A (ja) 2004-12-24 2008-07-17 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル 糖結合体ワクチン
JP2009532439A (ja) 2006-04-07 2009-09-10 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
JP2010500354A (ja) 2006-08-07 2010-01-07 プレジデント アンド フェロウズ オブ ハーバード カレッジ タンパク質マトリックスワクチンおよびそのようなワクチンの製造方法および投与方法
JP2010532793A (ja) 2007-06-20 2010-10-14 バクスター・インターナショナル・インコーポレイテッド コンジュゲートワクチン用修飾多糖
JP2010531329A (ja) 2007-06-26 2010-09-24 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 肺炎連鎖球菌莢膜多糖コンジュゲートを含むワクチン
JP2013518891A (ja) 2010-02-09 2013-05-23 メルク・シャープ・エンド・ドーム・コーポレイション １５価肺炎球菌多糖−タンパク質コンジュゲートワクチン組成物
JP2013521315A (ja) 2010-03-09 2013-06-10 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 担体タンパク質にコンジュゲートされた肺炎連鎖球菌多糖類を含んでなる免疫原性組成物
JP2015522692A (ja) 2012-07-16 2015-08-06 ファイザー・インク 糖およびその使用
JP2015524839A (ja) 2012-08-16 2015-08-27 ファイザー・インク 糖鎖付加プロセスおよび組成物
JP2017509656A (ja) 2014-01-21 2017-04-06 ファイザー・インク コンジュゲート化莢膜糖類抗原を含む免疫原性組成物およびその使用
JP2017505792A (ja) 2014-02-14 2017-02-23 ファイザー・インク 免疫原性糖タンパク質コンジュゲート
WO2015175355A1 (en) 2014-05-11 2015-11-19 Kanvax Biopharmaceuticals Ltd Compositions and methods of enhancing immunogenicity of polysaccharide protein conjugates
WO2016207905A2 (en) 2015-06-23 2016-12-29 Biological E Limited Multivalent pneumococcal conjugate vaccine
WO2017085586A1 (en) 2015-11-20 2017-05-26 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HUANG, Q., et al.，"PEG as a spacer arm markedly increases the immunogenicity of meningococcal group Y polysaccharide conjugate vaccine."，JOURNAL OF CONTROLLED RELEASE，2013年11月28日，Vol.172, No.1，pp.382-389，DOI: 10.1016/j.jconrel.2013.03.008，EPUB 17 March 2013

Also Published As

Publication number Publication date
CN118356485A (zh) 2024-07-19
MY198400A (en) 2023-08-28
AU2018280272A1 (en) 2020-01-30
CA3066911C (en) 2022-05-24
EP3634481A4 (en) 2021-07-21
KR20240018698A (ko) 2024-02-13
MX2023009362A (es) 2023-08-16
BR112019026192B1 (pt) 2022-05-10
KR20240018697A (ko) 2024-02-13
MX2019014829A (es) 2020-08-17
CA3066911A1 (en) 2018-12-13
AU2018280272B2 (en) 2021-01-28
BR112019026192A2 (pt) 2020-06-30
KR102634811B1 (ko) 2024-02-06
US10688170B2 (en) 2020-06-23
JP2020523323A (ja) 2020-08-06
AU2018280272C1 (en) 2021-05-06
CN111132691A (zh) 2020-05-08
WO2018227177A1 (en) 2018-12-13
EP3634481A1 (en) 2020-04-15
ZA201908528B (en) 2020-09-30
KR20200014921A (ko) 2020-02-11
US20180353591A1 (en) 2018-12-13

Similar Documents

Publication Publication Date Title
JP7132954B2 (ja) 改善された免疫原性及び結合活性を提供する２価又は多価コンジュゲート多糖を含む多価コンジュゲートワクチン
US12251438B2 (en) Immunogenic compositions of polysaccharide-protein pegylated compounds
JP2025122002A (ja) コンジュゲート化莢膜糖類抗原を含む免疫原性組成物、それを含むキットおよびこれらの使用
JP6808658B2 (ja) 多価肺炎球菌コンジュゲートワクチン
RU2634405C2 (ru) Иммуногенная композиция
US12053515B2 (en) Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24F
US7812006B2 (en) Conjugates obtained by reductive amination of the pneumococcus serotype 5 capsular polysaccharide
AU2021207701A1 (en) Multivalent Streptococcus vaccines
US20250195640A1 (en) Immunogenic Compositions of Polysaccharide-Protein Pegylated Compounds
KR20200005458A (ko) 다가 폐렴구균 다당체-단백질 접합체를 포함하는 면역원성 조성물, 및 이를 포함하는 약학 조성물
HK40023130B (zh) 包含缀合荚膜糖抗原的免疫原性组合物及其用途
WO2021214179A2 (en) Synthetic streptococcus pneumoniae saccharide conjugates to conserved membrane protein
HK40021072B (zh) 包含缀合荚膜糖抗原的免疫原性组合物及其用途
CN110652585A (zh) 多糖-蛋白缀合物免疫制剂及其制备与应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210318

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210318

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220510

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220802

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220824

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220826

R150 Certificate of patent or registration of utility model

Ref document number: 7132954

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250